Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines

Molecules

Volumn 13, Issue 6, 2008, Pages 1427-1440

  Lv, Jin Ling ^a   Wang, Rui ^a   Liu, Dan ^a   Guo, Gang ^a   Jing, Yong Kui ^b   Zhao, Lin Xiang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

1,2,3 Benzotriazine; Antiproliferative activity; Synthesis; Vatalanib succinate

Indexed keywords

ANTINEOPLASTIC AGENT; PHTHALAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TRIAZINE DERIVATIVE; VATALANIB;

ANIMAL; ARTICLE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; HUMANS; PHTHALAZINES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 46749129056     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules13061427     Document Type: Article

References (18)

1. Ferrara, N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9, Suppl 1, 2-10.
2. Poon, R. T.; Fan, S. T.; Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 2001, 19, 1207-1225.
3. Toi, M.; Matsumoto, T.; Bando, H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2001, 2, 667-673.
4. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K.-H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F.; Marme, D. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factorinduced responses and tumor growth after oral administration. Cancer Res. 2000, 60, 2178-2189.
5. Bold, G.; Altmann, K. H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Bruggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rosel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lasser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
6. Heymach, J. V. ZD6474 - Clinical experience to date. Brit. J. Cancer 2005, 92 Suppl 1, S14-20.
7. Sahtornsumetee, S.; Rich, J. N. Vandetanib (ZD6474), a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today 2006, 42, 657-670.
8. Joensuu, H.; De Braud, F.; Coco, P.; De Pas, T.; Putzu, C.; Spreafico, C.; Bono, P.; Bosselli, S.; Jalava, T.; Laurent, D.; Casali, P. G. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann. Oncol. 2008, 19, 173-177.
9. Thomas, A. L.; Trarbach, T.; Bartel, C.; Laurent, D.; Henry, A.; Poethig, M.; Wang, J.; Masson, E.; Steward, W.; Vanhoefer, U.; Wiedenmann, B. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann. Oncol. 2007, 18, 782-788.
10. Kovacs, M. J.; Reece, D. E.; Marcellus, D.; Meyer, R. M.; Mathews, S.; Dong, R. P.; Eisenhauer, E. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145. Invest. New Drugs 2006, 24, 529-535.
11. Lee, D. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin. Llung Cancer 2005, 7, 89-91.
12. Miller, K. D.; Trigo, J. M.; Wheeler, C.; Barge, A.; Rowbottom, J.; Sledge, G.; Baselga, J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res. 2005, 11, 3369-3376.
13. Gueto, C.; Ruiz, J. L.; Torres, J. E.; Méndez, J.; Vivas-Reyes, R. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA. Bioorg. Med. Chem. 2008, 16, 2439-2447.
14. Noronha, G.; Barrett, K.; Cao, J.; Dneprovskaia, E.; Fine, R.; Gong, X.; Gritzen, C.; Hood, J.; Kang, X.; Klebansky, B.; Li, G.; Liao, W.; Lohse, D.; Mak, C. C.; McPherson, A.; Palanki, M. S.; Pathak, V. P.; Renick, J.; Soll, R.; Splittgerber, U.; Wrasidlo, W.; Zeng, B.; Zhao, N.; Zhou, Y. Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5546-5550.
15. Wissner, A.; Floyd, M. B.; Johnson, B. D.; Fraser, H.; Ingalls, C.; Nittoli, T.; Dushin, R. G.; Discafani, C.; Nilakantan, R.; Marini, J.; Ravi, M.; Cheung, K.; Tan, X.; Musto, S.; Annable, T.; Siegel, M. M.; Loganzo, F. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. J. Med. Chem. 2005, 48, 7560-7581.
16. Siddiqui, M. S. S.; Stevens, M. F. G. Triazines and related products. Part XI. Dimroth rearrangements of 3-substituted 3,4-dihydro-4-imino-1,2,3- benzotriazines in acetic acid. J. Chem. Soc., Perkin Trans. 1, 1974, 609-610.
17. Hess-Stumpp, H.; Haberey, M.; Thierauch, K. H. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 2005 6, 550-557.
18. Lu, M.; Xia, L.; Luo, D.; Waxman, S.; Jing, Y. Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene 2004, 23, 3945-3952.